Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244111 | 0.78 | DAO (0.51) | DAOGRIN1F7F3HPGD | |
| SCHEMBL1244189 | 0.78 | SMYD3 (0.54) | DAOHPGDBLMKDM4EALOX15 | |
| SCHEMBL1244129 | 0.78 | DAO (0.51) | DAOGRIN1F7F3HPGD | |
| SCHEMBL1245121 | 0.76 | ALOX15 (0.55) | HPGDMEN1KMT2AKDM4EALOX15 | |
| SCHEMBL6627435 | 0.75 | DAO (0.49) | DAOGRIN1F7F3HPGD | |
| SCHEMBL1244211 | 0.74 | DAO (0.47) | DAOGRIN1F7F3HPGD | |
| SCHEMBL27350271 | 0.73 | DAO (0.50) | DAOGRIN1HPGDBLMMEN1 | |
| SCHEMBL13175413 | 0.70 | DAO (0.44) | DAOHPGDBLMCYP2C9KDM4E | |
| SCHEMBL3264194 | 0.70 | DAO (0.44) | DAOGRIN1HPGDKDM4EGRIN2D | |
| SCHEMBL1245077 | 0.69 | DAO (0.46) | DAOGRIN1F7F3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| US-6576653-B2 | For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis | PFIZER INC. | 2003-06-10 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2001-11-29 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125580-A2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | DAO 1915/4885GRIN1 1731/4885F7 2377/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | DAO 69/4885GRIN1 4314/4885F7 1244/4885 |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | PYGM, GYS1, PYGL | DAO 1094/4885GRIN1 4774/4885F7 2651/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | DAO 1344/4885GRIN1 927/4885F7 1022/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | DAO 1906/4885GRIN1 1875/4885F7 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.